Retained cholesterol crystal seeds may amplify skin inflammation after repeated damage and repair
In sterile skin models, retained cholesterol crystal seeds could amplify inflammation after a break despite equal drug exposure and total cholesterol. Persistent amplification after crystal removal, with cell viability unchanged, would refute this hypothesis.
Stage of verification
- Hypothesis published2026-09-25
- Indirect evidenceAssessed at 4 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Biological function
The biological function description is being prepared
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.
Aggregate or deposit
Cholesterol crystals
Cholesterol in a crystalline state, including stable seeds from which larger crystals can grow
Where this hypothesis actsSkin undergoing repeated cycles of damage and repair, with crystal seeds persisting through treatment breaks
Hypotheses on this target 1
Clearance restoration
Neutralisation
Accelerated excretion
Disaggregation1
Aggregation prevention
What is proposed
Disaggregation
Prevent crystal seed formation or eliminate existing seeds
With whatNot stated in the record
HowSelectively dissolve crystals while preserving membrane cholesterol and cell viability, restoring the previous total cholesterol content in noncrystalline form
Possible result
Possible prevention of the amplified inflammatory response during repeated exposure and stabilization of SPV_11
From the recordПредотвращение зародышеобразования или устранение зародышей должно стабилизировать SPV_11.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
Skin repair might leave behind material that makes the next injury provoke more inflammation. The unexpected move is to place that lasting record in the physical form of cholesterol, a substance found in cell membranes, rather than simply in how much drug remains. This is a proposal generated by the pipeline, not a measured result: tiny surviving crystals are proposed to accelerate crystal growth when injury resumes.
- Repeated injury and repair are proposed to release cholesterol from cell membranes into small regions of skin.
- Local cholesterol is proposed to exceed the amount that can remain without forming crystals.
- A rare first stable crystal is proposed to create a persistent seed.
- Some seeds are proposed to survive the treatment break.
- The next injury would switch crystal formation from waiting for a rare first seed to growth on seeds already present.
- Faster crystal growth would increase inflammation without requiring more total cholesterol or greater drug exposure.
A few ice crystals left in a partly thawed drink give new ice a place to grow when it gets cold again. The amount of water need not change for its previous freezing to affect what happens next.
Where the picture breaks: The proposal concerns cholesterol released during skin injury, not water freezing through cooling. The picture does not establish that cholesterol seeds survive in skin, accelerate later growth, or cause inflammation.
- Master questionstep 01 of 04
The goal is a therapy that brings the functioning of middle-aged human skin closer to that of young people.
Rests on: This is the supplied research goal; it does not establish that such a therapy is achievable.
Stated in the chain - Goal pillarstep 02 of 04
Limiting damage that accumulates through repeated repair is treated as one route toward younger skin function.
Rests on: The goal concerns skin function, but does not specify repeated repair as a cause of its decline.
AssumptionThe chain assumes that cumulative damage from repeated repair contributes to the functional difference between middle-aged and young skin, and that limiting it would help close that difference.
- Gap questionstep 03 of 04
A stronger reaction after a treatment break could reflect something left behind by earlier treatment. The question asks whether that reaction persists at the same drug concentration in tissue, and whether eliminating remaining drug prevents irritation from increasing after repeated restarts.
Rests on: The preceding stage identifies cumulative damage from repair, but supplies no treatment or observation connecting that damage to drug persistence and restarting therapy.
LeapThe missing bridge is an account of why repeated drug treatment and irritation after restarting are the relevant form of accumulated repair damage for the original goal.
- Hypothesisstep 04 of 04
Cholesterol released from damaged cell membranes is proposed to form persistent crystal seeds. After a break, those seeds would help crystals grow faster and intensify inflammation even when drug exposure and total cholesterol are unchanged.
Rests on: The preceding question supplies the need to explain a stronger response after a break at matched drug exposure. The endpoint supplies a physical explanation and explicitly borrows a model in which the first stable crystal forms rarely and unpredictably, while a surviving seed lets later growth bypass that first event.
Stated in the chain
What is carried, and what is not. Screened sources speak to two component links: cholesterol accumulation leading to crystals, reported in Journal of Biomedical Research in 2017 in a disease involving material shed from artery deposits, and crystals promoting inflammation, reported in Science in 2015 in mice with diseased arteries; neither establishes the proposed sequence in repeatedly injured skin. Research in 2023 also reported crystals after spinal cord injury in young adult mice, but does not establish retained seeds driving a faster response after a break; no supplied source establishes the sequence end to end.
Where the reasoning is carried by something unstated · 2
- Goal pillar. The chain assumes that cumulative damage from repeated repair contributes to the functional difference between middle-aged and young skin, and that limiting it would help close that difference.
- Gap question. The missing bridge is an account of why repeated drug treatment and irritation after restarting are the relevant form of accumulated repair damage for the original goal. Establish the missing link before relying on this step.
How a result here could mislead · 3
- Reduced inflammation after dissolving crystals could be credited to seed removal when the treatment also changes membrane cholesterol or damages cells. Conversely, continued inflammation could be called a refutation even though some seeds remain. What closes it: Crystal removal must be verified alongside cell survival and preservation of membrane cholesterol. Total cholesterol must be measured separately and restored in noncrystalline form as specified; the supplied design acknowledges that achieving this selectivity remains unresolved.
- Equal total drug concentration could be mistaken for equal active drug exposure. The rival involving stored drug predicts that the next application releases previously bound drug, producing a brief additional peak despite matching totals before treatment resumes. What closes it: Matching must cover where and when the unbound active drug and its active breakdown products occur during the renewed treatment, not just total tissue concentration before it.
- Inflammation after adding crystals back could be mistaken for proof that crystals preserved the history of earlier injury. Newly added crystals might provoke inflammation without establishing persistence through the break or accelerated growth in the next cycle. What closes it: The test must track crystals through the break and show that their growth precedes the stronger response after renewed injury. The specified equal-mass noncrystalline comparison and models verified to be free of microorganisms are needed to separate physical form from cholesterol amount and from the bacterial-virus rival.
What would make this wrong. The hypothesis explicitly predicts its own refutation: the stronger response persists after verified elimination of all cholesterol crystals while cell survival remains unchanged. Interpreting that result also requires the stated matching of drug exposure and restoration of total cholesterol in noncrystalline form; otherwise the intended comparison has not been achieved.
What it would change. If this held, repeated repair could worsen skin responses through retained physical material even after drug exposure has been matched. Work toward improving middle-aged skin function would then need to account for whether treatment leaves cholesterol crystals that make later injury more inflammatory. Demonstrating this in experimental skin models would still not establish that removing those crystals restores youthful function in middle-aged people, or that such removal is achievable without damaging skin.
Sources read · 9
Atheroembolic renal disease. · Lancet (London, England) · 2010
“Embolisation often affects other organs, such as the skin, gastrointestinal system, and brain.”
Does not settle: It does not establish repeated skin damage and repair, local cholesterol supersaturation, retained crystal seeds, phase-state-dependent inflammation, or effects of preventing or clearing crystal nucleation.
Cholesterol embolization syndrome. · Current opinion in cardiology · 2011
“CES (also referred to as cholesterol crystal embolization, atheromatous embolization or atheroembolism) occurs when cholesterol crystals and other contents of an atherosclerotic plaque embolize from a large proximal artery to smaller distal arteries, causing ischemic end-organ damage.”
Does not settle: Источник не устанавливает образование или сохранение кристаллических зародышей в коже после повторных повреждений, их влияние на последующие циклы воспаления, фазовое состояние холестерина при одинаковом его общем содержании или эффект устранения зародышей на SPV_11.
[Postinterventional cholesterol crystal embolization]. · Deutsche medizinische Wochenschrift (1946) · 2007
“Both biopsies showed cholesterol crystal emboli with elongated, biconvex transparent clefts and an inflammatory reaction of the vessel wall which had caused obstruction.”
Does not settle: Источник не устанавливает образование или сохранение кристаллических зародышей в коже после повторных повреждений и восстановления, их влияние на последующий воспалительный ответ, фазовое состояние холестерина при одинаковом общем содержании или эффект предотвращения и устранения зародышей.
Cholesterol crystal embolization following plaque rupture: a systemic disease with unusual features. · Journal of biomedical research · 2017
“Free cholesterol build-up in the extracellular space leads to crystallization.”
Does not settle: This source does not establish the proposed process in skin, repeated damage-and-repair cycles, persistence of crystal seeds after a break, equal total cholesterol or drug exposure, or effects of preventing or removing seeds on SPV_11.
NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. · Circulation research · 2018
“NLRP3 is activated by various endogenous danger signals abundantly present in atherosclerotic lesions, such as oxidized low-density lipoprotein and cholesterol crystals.”
Does not settle: Источник описывает атеросклеротические поражения. Он не устанавливает процессы в коже, последствия повторных циклов повреждения и восстановления, сохранение кристаллических зародышей после перерыва, роль одинаковой лекарственной экспозиции и общего содержания холестерина или влияние предотвращения и устранения зародышей на SPV_11.
NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. · Journal of hepatology · 2017
“Addition of cholesterol crystals to KCs produced similar results, albeit the magnitude of IL-1β release was less ( vs . ).”
Does not settle: Источник показывает воспалительный ответ на кристаллы холестерина в клетках Купфера, но не проверяет повторные повреждения и восстановление кожи, сохранение кристаллических зародышей после перерыва, одинаковое общее содержание холестерина, фазовое состояние холестерина или стабилизацию SPV_11.
Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. · Science (New York, N.Y.) · 2015
“Using a murine model of atherosclerosis, we show that cholesterol crystals acted both as priming and danger signals for IL-1β production.”
Does not settle: It does not establish repeated damage-and-repair cycles, retention or persistence of crystal seeds after a break, skin inflammation, identical drug exposure or total cholesterol with different phase states, or whether preventing or removing seeds stabilizes SPV_11.
DNA methyltransferase 1 deficiency improves macrophage motility and wound healing by ameliorating cholesterol accumulation. · NPJ Regenerative medicine · 2023
“Free cholesterol (FC) is generated in the lysosome following degradation of the taken-up lipoproteins and can be transported to the endoplasmic reticulum to be esterified by the sterol O-acyltransferase 1 (SOAT1/ACAT1).”
Does not settle: The source text does not establish cholesterol crystal nucleation or persistence, repeated damage-and-repair cycles, phase-state-dependent inflammation at equal total cholesterol, or whether preventing or removing crystals stabilizes SPV_11.
Unresolved Excess Accumulation of Myelin-Derived Cholesterol Contributes to Scar Formation after Spinal Cord Injury. · Research (Washington, D.C.) · 2023
“Using confocal reflection microscopy, we detected cholesterol crystals in spinal cord lesions as early as 7 dpi, which mediates inflammasome activation.”
Does not settle: This is a spinal-cord-injury study in young adult mice. It does not establish repeated damage-and-repair cycles, skin inflammation, retained seeds causing a faster response after a break, equal total cholesterol or drug exposure, or whether preventing or removing seeds stabilizes SPV_11.
The gap this hypothesis explains
Does restarting treatment worsen irritation at equal tissue drug levels, and does clearing leftover drug prevent worsening?
Original wording · exactly as the pipeline generated it
Сохраняется ли усиленная реакция после перерыва при одинаковой тканевой концентрации препарата, и предотвращает ли устранение остаточной экспозиции нарастание раздражения при повторном возобновлении терапии?
What this question is asking
The question concerns whether skin responds more strongly when drug treatment resumes after a break. It asks whether that stronger response remains when the amount of drug in the tissue is the same as during the earlier treatment. It also asks whether removing drug left over from earlier treatment prevents irritation from increasing across repeated restarts, compared with restarting while leftover drug remains. The wording assumes that a stronger response and progressively worsening irritation occur, but the supplied sources do not establish those patterns for the intended setting of improving skin function in middle-aged people.
- Tissue drug concentration
- The amount of a drug within a specified amount of tissue. Matching this measurement is the question's way of asking whether a stronger reaction can occur without a higher measured drug level.
- Residual exposure
- Continued exposure to drug left over from earlier treatment. The question asks whether eliminating this exposure prevents irritation from worsening; the supplied sources do not establish that it occurs in the intended setting.
- Drug clearance
- Removal of drug from the relevant tissue or body. Here, clearance means eliminating leftover drug rather than merely stopping further applications.
- Irritation
- An unwanted local reaction to treatment. The question does not specify which signs or symptoms count, how they are measured, or what would qualify as worsening.
- Inflammation
- A tissue response involving immune activity. S9 measures skin inflammation in mice; this outcome cannot automatically be treated as the same thing as treatment irritation in human skin.
- Contact sensitization
- Development of acquired allergic sensitivity to a substance that contacts the skin. It is a different outcome from irritation, so the absence reported in S1 does not settle the restart question.
- Allergic symptoms
- Symptoms attributed to an immune reaction against a substance. Their return after restarting a drug in S10 does not by itself establish stronger local irritation or increasing severity over successive restarts.
- Absorption
- Movement of an applied drug into tissue or into the wider body. Absorption studies address where drug goes, but do not necessarily establish how tissue reacts when treatment resumes.
- Psoriasis-like mouse model
- An experimental condition in mice intended to resemble aspects of psoriasis, an inflammatory skin disease. Its findings concern that model and do not directly establish the same response in human skin.
- Repeat challenge
- A renewed exposure used to provoke a response. S9 reports a repeat challenge at the same skin site, which is not enough to establish what happens during repeated restarts of the proposed therapy.
- Redistribution
- A change in where cells are located. S9 reports persistence of a redistribution pattern after withdrawal; this is not a measurement of drug remaining in tissue.
- Case report
- A description of an individual clinical case. S10 establishes what was reported in that case, without establishing how commonly the response occurs.
An enhanced response occurs after a treatment break, and irritation increases with repeated treatment restarts.
The assumption is that tissue reacts more strongly after treatment resumes and that irritation builds across successive restarts. Drug remaining in the tissue is treated as a possible contributor to that pattern. Establishing the pattern would provide the effect whose dependence on leftover drug the question asks about.
S9 reports more severe skin inflammation after a repeat challenge at the same site in previously treated mice, supporting a narrower version of a stronger response after withdrawal. S10 reports the return of allergic symptoms after one drug restart, which establishes recurrence in that case rather than progressive irritation. Neither establishes increasing irritation across repeated restarts in middle-aged human skin, and neither tests matched tissue drug levels or removal of residual exposure.S9S10
The same question asked without the part nothing read establishes:
- At the same tissue drug level, is skin irritation greater after restarting treatment than during the earlier treatment period?
- Does removing drug remaining from earlier treatment change skin irritation across repeated treatment restarts?
- Stronger response persists; clearing leftover drug prevents worsening This combination would indicate that the measured tissue drug level alone does not explain the stronger response after a break. It would also support a contribution from leftover drug to worsening across restarts, without establishing that both effects have the same cause.
- Stronger response persists; clearing leftover drug does not prevent worsening The stronger response would remain despite matching tissue drug levels. Removing leftover drug would therefore be insufficient to prevent worsening, and treating clearance as protection against irritation would be unsupported.
- Stronger response disappears; clearing leftover drug prevents worsening The comparison would provide no evidence of a stronger response at equal tissue drug levels. Prevention of worsening after clearance would support a contribution from leftover exposure, although it would not establish the full mechanism.
- Stronger response disappears; clearing leftover drug does not prevent worsening The comparison would provide no evidence of a stronger response at equal tissue drug levels. Failure of clearance to prevent worsening would also leave leftover drug insufficient as an explanation for any increase in irritation across restarts.
Drug remaining in tissue could contribute to exposure when treatment resumes; this is a possibility posed by the question, not a finding established by the supplied sources. If a stronger response persisted at the same tissue drug level, the measured level alone would not explain the difference. If removing leftover drug prevented worsening, that would support a contribution from continued exposure between treatment periods. Confusing these possibilities could lead to an unsupported expectation that a treatment break or drug clearance prevents irritation, while the supplied evidence also does not establish improved skin function.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
Проверяемая гипотеза: повторные циклы повреждения и восстановления создают локальное пересыщение свободным холестерином из клеточных мембран. Редкое образование устойчивого кристаллического зародыша оставляет физический носитель предыстории. После перерыва сохранившиеся зародыши ускоряют увеличение кристаллической фракции при следующем цикле и усиливают стерильное воспаление. Поэтому повышенный ответ сохраняется при одинаковой лекарственной экспозиции и одинаковом общем содержании холестерина, но зависит от его фазового состояния. Предотвращение зародышеобразования или устранение зародышей должно стабилизировать SPV_11.
Where the idea comes from
The hypothesis borrows a result from another field. This is what it borrows, and from where.
Стохастические процессы, активированное преодоление энергетического барьера по Крамерсу и пуассоновская модель первого зародышеобразования: J(t)=J0·exp[−ΔG*(t)/(kB·T)], P(τ≤t)=1−exp[−∫₀ᵗ V(s)J(s)ds]. J(t) означает число новых устойчивых кристаллических зародышей на единицу объёма кожи в единицу времени; J0 представляет частоту молекулярных попыток зародышеобразования на тот же объём; ΔG*(t) является барьером свободной энергии образования критического зародыша при локальном пересыщении холестерином; kB является постоянной Больцмана; T означает абсолютную температуру ткани; V(s) представляет объём локально пересыщенной ткани в момент s; τ означает время появления первого устойчивого зародыша; t и s обозначают время наблюдения и переменную интегрирования; P является вероятностью появления зародыша к моменту t. Это проверяемое приближение для редких независимых событий, а не установленный закон кожного раздражения. Сохранённые зародыши позволяют следующему циклу миновать стадию первичного зародышеобразования. [Исходная работа Крамерса](https://www.mit.edu/~kardar/research/seminars/translocation/Kramers1940.pdf).
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
В стерильных моделях кожи при повторных одинаковых воздействиях усилению ответа предшествует появление кристаллического холестерина. Устранение подтверждённых кристаллов с восстановлением прежнего общего содержания холестерина в некристаллической форме отменяет усиление. Внесение малой массы кристаллических зародышей возвращает его, тогда как равная масса некристаллического холестерина этого не делает. После удаления всех зародышей время до повторного возникновения эффекта становится случайным и зависит от объёма восприимчивой ткани; при сохранённых зародышах задержка сокращается. Сохранение усиления после устранения кристаллов при неизменной жизнеспособности опровергает гипотезу.
States a measurable outcome; comparing rivals needs more conditions. The prediction specifies observable loss and restoration of response enhancement, contrasting effects of crystalline and noncrystalline cholesterol, recurrence timing, and an explicit rejection condition. No rival prediction is supplied. Only a bench experiment would settle it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Фазовое состояние можно оценивать сочетанием рамановской микроскопии и методов электронной микроскопии с сохранением липидов. Общий холестерин измеряют отдельно. Главная экспериментальная трудность состоит в изменении кристаллической фракции без извлечения мембранного холестерина и самостоятельного повреждения клеток. До подтверждения такой избирательности результат растворения кристаллов будет неоднозначным.
Other explanations
Every other hypothesis the engine wrote for the same gap, and the observation that would separate the two.
В стерильных моделях кожи при повторных одинаковых воздействиях усилению ответа предшествует появление кристаллического холестерина. Устранение подтверждённых кристаллов с восстановлением прежнего общего содержания холестерина в некристаллической форме отменяет усиление. Внесение малой массы кристаллических зародышей возвращает его, тогда как равная масса некристаллического холестерина этого не делает. После удаления всех зародышей время до повторного возникновения эффекта становится случайным и зависит от объёма восприимчивой ткани; при сохранённых зародышах задержка сокращается. Сохранение усиления после устранения кристаллов при неизменной жизнеспособности опровергает гипотезу.
- What would separate them
Virus replication in skin bacteria may amplify irritation when therapy resumes predicts: В колонизированных моделях кожи усиленный ответ сохраняется после подтверждённого удаления препарата. Очищенная фаговая фракция переносит способность к усиленному ответу в ранее не подвергавшуюся терапии модель с теми же бактериями; эффект воспроизводится при последовательном переносе через новые культуры после разведения исходных растворимых медиаторов ниже действующих концентраций. Избирательное прекращение фаговой репликации устраняет усиление при сохранении бактериальной нагрузки. Удаление кристаллов холестерина эффекта не устраняет. Отсутствие переноса и сохранение реакции после подтверждённого прекращения репликации опровергают гипотезу.
- Rival 02 of 02What would separate them
Competition for tissue binding sites may release retained drug and worsen skin irritation predicts: После первого курса с изотопно меченным препаратом нанесение основы без новой дозы действующего вещества вызывает кратковременное повышение свободной меченой формы и раздражение. Эффект зависит от способности компонентов основы вытеснять препарат в независимом опыте связывания. После удаления связанного остатка всплеск исчезает; его воспроизведение в ранее не обработанной ткани воспроизводит выраженность повреждения. При одинаковых полных профилях свободной активной формы ранее обработанная и контрольная кожа отвечают одинаково. Сохраняющееся различие после такого выравнивания опровергает гипотезу в пользу самостоятельного носителя предыстории.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
This hypothesis states no figure and cites no study, so there is nothing here to trace.
What it would take to refute it. Nothing already retrieved carries the prediction’s terms and it names no measurement this layer can route to a public dataset, so the bench is the residual — not a finding against it.
0 citation handles extracted; 1 Europe PMC search run; 0 records examined; 0 sources stored for enrichment, 0 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.